Takeda takes $140M charge on failed epilepsy drug, while touting continued FDA potential

We already know that Takeda is hoping to find a path to the FDA for epilepsy medicine soticlestat despite a phase 3 miss but the Japanese pharma has now revealed that the clinical trial failure will cost the company about $140 million.